AVXL
2.97 USD
+0.00%
Today
-3.96%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 11:00 PM
Tue
4:30 PM ~ 11:00 PM
Wed
4:30 PM ~ 11:00 PM
Thu
4:30 PM ~ 11:00 PM
Fri
4:30 PM ~ 11:00 PM
Sat
Closed
Information
Name
Anavex Life Sciences Leveraged
Currency
USD
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0191%
Overnight Fees Sell
0.0024%
Market Cap
277.09M
Avg Daily Volume
3.23M
52 Week High
13.99 USD
52 Week Low
2.61 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01910% | $(0.191) |
| SELLS | 0.00240% | $0.024 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Top News
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
tradingview.com
3d ago
Anavex Life Sciences Provides Comprehensive Regulatory Update
tradingview.com
1w ago
ADMA.Biologics
-3.12%
Alexandria
-3.37%
AST.SpaceMobile
+2.78%
Anavex
-3.96%
Beam_Therapeutics
+4.20%
Bunge
+0.71%
BWX_Tech
-0.43%
BostonProp
+1.07%
Chewy
-2.86%
Corcept
-0.85%
Cintas
+0.43%
Chevron
-0.53%
Draftkings.inc
-0.04%
DigitalOcean
-13.30%
Devon
+0.23%
Figma
-4.58%
Generac
+0.23%
GoPro
+4.23%
Honeywell
-0.45%
JetBlue
-3.88%
JPMorgan
+0.09%
KB_Home
-1.15%
Kilroy
+1.48%
Liberty.Energy
+1.10%
LockheedM
-1.76%
MarathonP
+0.07%
MicronTech
-0.08%
NewmontM
+2.35%
NatOilwell
-0.46%
Occidental
+0.00%
PaychexInc
-2.76%
Pinduoduo-Inc
-0.08%
Phillips66
-0.53%
Rocket-Lab
+1.31%
SLGreen
+0.95%
SanDisk.Corp
+0.16%
Sarepta
-4.83%
Tempus.AI
-2.73%
Terns.Pharma
+0.06%
10X_Genomics
+1.53%
Valero
+1.57%
Vornado
+1.42%
WesternDig
+1.64%
ExxonMobil
-1.24%
BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
reuters.com
2w ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
